Methods to detect granulocytic ehrlichiosis

Details Methods to detect granulocytic ehrlichiosis Methods to detect granulocytic ehrlichiosis

1997-03-21

2002-06-11

Smith, Lynette R. F. (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S185100, C424S190100, C424S136100, C424S191100, C424S192100, C424S234100, C424S241100, C530S300000, C530S350000, C530S380000, C530S387100, C530S388400, C530S388700, C530S827000, C435S069100, C435S069300

Reexamination Certificate

active

06403093

ABSTRACT:

BACKGROUND OF THE INVENTION
Human granulocytic ehrlichiosis (HGE) is a recently described illness caused by a bacterial species that is phylogenetically similar to, or conspecific with, an ehrlichial genogroup comprising the veterinary pathogens
Ehrlichia equi
and
E. phagocytophilia
(Chen et al.,
J. Clin. Micro
., 32, 589 (1994); Dumler et al.,
J. Clin. Micro
., 33, 1098 (1995)). The only vectors demonstrated to transmit the HGE agent are Ixodes sp. ticks, although anecdotal evidence suggests that the American dog tick (
Dermacentor variabilis
) may also be implicated in HGE transmission. HGE typically presents as an acute febrile illness with headache, myalgias, leukopenia, thrombocytopenia, and elevated levels of alkaline phosphatase, lactate dehydrogenase, and aminotransferases (Bakken et al.,
JAMA
, 272, 212 (1994); Bakken et al.,
JAMA
, 275, 199 (1996); Pancholi et al.,
J. Infect, Dis
, 172, 1007 (1995); Telford et al.,
Proc. Natl. Acad. Sci USA
, 93, 6209 (1996)). Severe cases, when left untreated, may be fatal.
For the direct recovery of the HGE agent from clinical specimens, mouse inoculation, molecular detection, or cultivation of the organism in HL60 cells have been used. However, the duration of bacteremia with the HGE agent is not known, so the reliability of these tests beyond the acute stage of the illness has not been established. Antibody tests based on seroconversion to
E. equi
antigen have been used to identify infected persons after the initial stage of the illness (Bakken et al.,
JAMA
, 272, 212 (1994); Bakken et al.,
JAMA
, 275, 199 (1996)). However, the indirect fluorescent antibody (IFA) assay based on
E. equi
antigen is labor intensive, not widely available, and the interpretation of results is often subject to substantial individual variation (Bakken et al.,
JAMA
, 275, 199 (1996); Dumler et al., supra; Dumler et al.,
Dermat. Clinics
, 12, 25 (1994)).
Thus, what is needed is an improved method to detect the presence of an infectious agent associated with HGE.
SUMMARY OF THE INVENTION
The present invention is based upon the direct recovery (or isolation) of a gene encoding an immunogenic polypeptide associated with granulocytic ehrlichiosis in humans from patient tissues. Direct recovery of genes encoding immunodominant antigens from infected tissues, i.e., without prior growth in culture, is particularly useful to prepare immunodiagnostic reagents for emerging, uncultured, or difficult to culture, pathogens, e.g., the agents associated with human granulocytic ehrlichiosis (HGE),
Tropheryma whippelii
, the bacillary agent associated with Whipple's disease, and other organisms related to mycobacteria which are yet to be cultivated in vitro. Moreover, direct recovery of DNA comprising open reading frames can also facilitate development of customized immunodiagnostic reagents, even when recovery of the infectious agent is not possible or when extensive agent variability (i.e., “quasispecies”) precludes development of universal immunodiagnostic reagents.
Thus, the invention provides an isolated and purified DNA molecule comprising a preselected DNA sequence encoding an immunogenic polypeptide, a biologically active subunit, or a biologically active variant thereof, the presence of which is associated with granulocytic ehrlichiosis in a mammal, e.g., in humans. Preferably, the preselected DNA sequence encodes an immunogenic polypeptide which is specifically associated with the agent which causes human granulocytic ehrlichiosis (HGE). A preferred embodiment of the invention provides a preselected DNA sequence which encodes an immunogenic polypeptide having an amino acid sequence comprising SEQ ID NO:2, e.g., the preselected DNA sequence comprises SEQ ID NO:1. The invention further provides an isolated and purified DNA molecule which is complementary to SEQ ID NO:1.
The invention also provides an expression cassette comprising a preselected DNA sequence operably linked to a promoter functional in a host cell wherein said DNA sequence encodes an immunogenic polypeptide, a biologically active variant or subunit thereof, wherein said polypeptide is associated with granulocytic ehrlichiosis in a mammal. The expression of the preselected DNA sequence in host cells yields a polypeptide which is an ehrlichial antigen. Preferably, the expression cassette of the invention comprises a preselected DNA sequence encoding an immunogenic fusion polypeptide, a portion of which comprises an ehrlichial-specific polypeptide. The remainder of the DNA sequence preferably encodes a polypeptide that enhances the immunogenicity of the fusion polypeptide in vivo.
As used herein, “an immunogenic polypeptide associated with granulocytic ehrlichiosis” is preferably a polypeptide having the amino acid Li sequence comprising SEQ ID NO:2, as well as variants of SEQ ID NO:2 which have at least about 80%, preferably at least about 90%, and more preferably at least about 95%, identity or homology to SEQ ID NO:2, or a biologically active subunit thereof. Biologically active subunits of the immunogenic polypeptide of the invention, and biologically active variants of the immunogenic polypeptide of the invention and subunits thereof, falling within the scope of the invention have at least about 10%, preferably at least about 50%, and more preferably at least about 90%, the activity of the polypeptide comprising SEQ ID NO:2. The activity of an immunogenic polypeptide of the invention can be measured by methods well known to the art including, but not limited to, the ability of the polypeptide to be bound by antibodies specific for the infectious agent associated with granulocytic ehrlichiosis (see Example II), or the ability of the polypeptide to elicit a sequence-specific immunologic response when the polypeptide is administered to an organism, e.g., a mammal such as rabbit, goat, sheep, rat or mouse. Preferably, the immunologic response is a humoral response, i.e, antibody response, directed to a particular epitope on the polypeptide. More preferably, the presence of antibodies specific for that epitope correlates with the granulocytic ehrlichiosis infection status of the organism.
Further provided is an isolated and purified immunogenic polypeptide, a biologically active subunit or variant thereof, which is associated with granulocytic ehrlichiosis in a mammal. The polypeptide is useful to detect the presence of antibodies in mammals, e.g., deer, mice, rats, dogs and humans, which are specific for an infectious agent associated with granulocytic ehrlichiosis. Preferably, the polypeptide has an amino acid sequence comprising SEQ ID NO:2. The isolated and purified polypeptides of the invention are useful to prepare an immunogenic composition, such as a vaccine comprising the polypeptide, in combination with a pharmaceutically acceptable carrier, wherein the administration of the immunogenic composition or vaccine to a mammal induces the production of antibodies to the polypeptide. In particular, an immunogenic composition or vaccine which comprises a polypeptide having an epitope which is specific for the agent associated with human granulocytic ehrlichiosis is preferred.
The invention provides a method of expressing a nucleic acid molecule encoding an immunogenic polypeptide, the presence of which is associated with granulocytic ehrlichiosis, in a cultured host cell stably transformed with a chimeric vector comprising said nucleic acid molecule operably linked to control sequences recognized by the host cell transformed with the vector, and recovering the polypeptide from the host cell.
The invention fturther provides a diagnostic method comprising contacting an amount of DNA obtained from a physiological sample which comprises cells from a mammal at risk of, or afflicted with, granulocytic ehrlichiosis, with an amount of at least two complementary oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified DNA. At least one oligonucleotide binds specifically to a DNA sequence encoding a polypeptide

Affiliated with

Also associated with

Rating

Methods to detect granulocytic ehrlichiosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods to detect granulocytic ehrlichiosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to detect granulocytic ehrlichiosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2920067